A participant died in a clinical trial of a Federal Drug Administration-approved antibody treatment for Alzheimer’s disease, and the death may be linked to the drug, a new case report reveals. The case, published in May in the Journal of Alzheimer’s Disease, details unreported adverse outcomes associated with the use of Lecanemab (Lequembi), an anti-amyloid…
2 Fast-Approved Anti-Amyloid Alzheimer’s Drugs Raise Concerns
Over the past two years, two Alzheimer’s disease drugs were approved under accelerated approval. Both drugs are based on popular amyloid beta-plaque theories, yet both have raised questions. On Jan. 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb), a new monoclonal antibody that seems to slow cognitive decline in some Alzheimer’s patients. In…
-
Recent Posts
-
Archives
- May 2025
- April 2025
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- September 2013
- July 2013
- March 2013
- January 2013
- December 2012
- November 2012
- December 1
-
Meta